Since then, IFN‐γ signaling, both in tumor cells and in the TME, has emerged as a pivotal effector of antitumor immunity during the “elimination” and “equilibrium” phase of cancer immunoediting and correlates positively with clinical responses to immunotherapies (Ivashkiv, 2018; Alspach et al, 2019). This evidence concerns the gene IFNG and neoplasm.